NO20032181L - Anvendelse av CCI-779 som et antineoplastisk middel - Google Patents

Anvendelse av CCI-779 som et antineoplastisk middel

Info

Publication number
NO20032181L
NO20032181L NO20032181A NO20032181A NO20032181L NO 20032181 L NO20032181 L NO 20032181L NO 20032181 A NO20032181 A NO 20032181A NO 20032181 A NO20032181 A NO 20032181A NO 20032181 L NO20032181 L NO 20032181L
Authority
NO
Norway
Prior art keywords
cci
antineoplastic agent
antineoplastic
agent
neoplasms
Prior art date
Application number
NO20032181A
Other languages
English (en)
Other versions
NO20032181D0 (no
Inventor
Jr James Joseph Gibbons
Philip Frost
Carolyn Mary Discafani-Marro
Gary Dukart
Lisa Anne Speicher
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20032181L publication Critical patent/NO20032181L/no
Publication of NO20032181D0 publication Critical patent/NO20032181D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives anvendelse av CCI-779 ved behandling av neoplasma.
NO20032181A 2000-11-15 2003-05-14 Anvendelse av CCI-779 som et antineoplastisk middel NO20032181D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24907700P 2000-11-15 2000-11-15
PCT/US2001/047324 WO2002040000A2 (en) 2000-11-15 2001-11-13 Use of cci-779 as an antineoplastic agent

Publications (2)

Publication Number Publication Date
NO20032181L true NO20032181L (no) 2003-05-14
NO20032181D0 NO20032181D0 (no) 2003-05-14

Family

ID=22941961

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032181A NO20032181D0 (no) 2000-11-15 2003-05-14 Anvendelse av CCI-779 som et antineoplastisk middel

Country Status (27)

Country Link
US (3) US20020091137A1 (no)
EP (1) EP1335725B1 (no)
JP (4) JP4472251B2 (no)
KR (1) KR100827942B1 (no)
CN (2) CN1678312A (no)
AR (1) AR031341A1 (no)
AT (1) ATE393629T1 (no)
AU (2) AU2731302A (no)
BR (1) BR0115323A (no)
CA (1) CA2429020C (no)
CY (1) CY1108109T1 (no)
DE (1) DE60133831T2 (no)
DK (1) DK1335725T3 (no)
EA (1) EA007096B1 (no)
ES (1) ES2305134T3 (no)
HU (1) HUP0400521A3 (no)
IL (2) IL155871A0 (no)
MX (1) MXPA03004192A (no)
NO (1) NO20032181D0 (no)
NZ (1) NZ539668A (no)
PL (1) PL207061B1 (no)
PT (1) PT1335725E (no)
SG (1) SG148031A1 (no)
SI (1) SI1335725T1 (no)
TW (1) TWI286074B (no)
WO (1) WO2002040000A2 (no)
ZA (1) ZA200304603B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
CN1551767A (zh) 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
PL367267A1 (en) * 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
EP1478648B1 (en) * 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
AU2003280437A1 (en) * 2002-06-27 2004-01-19 Microport Medical (Shanghai) Co., Ltd. Drug eluting stent
RU2344821C2 (ru) * 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
UA81265C2 (en) * 2002-09-17 2007-12-25 Wyeth Corp Granulate formulation of the rapamycin ester cci-779 and process for the preparation thereof
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
CA2515677A1 (en) * 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
AU2004235395A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
KR20060052880A (ko) * 2003-07-25 2006-05-19 와이어쓰 동결건조된 ｃｃｉ- 779 제형
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
DE602004011398T2 (de) * 2004-01-08 2009-01-15 Wyeth Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
JP2008530145A (ja) * 2005-02-15 2008-08-07 ワイス 経口投与可能なｃｃｉ−７７９製剤
EP3488866A1 (en) * 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
PT2275103E (pt) * 2005-11-21 2014-07-24 Novartis Ag Inibidores de mtor para o tratamento de tumores endócrinos
JP2009520818A (ja) * 2005-12-20 2009-05-28 ワイス 薬物物質不純物の制御によるｃｃｉ−７７９製剤安定性の制御
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
CA2975567A1 (en) * 2007-10-03 2009-04-09 Genesis Technical Systems Corp. Dynamic, asymmetric rings
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
US8716307B2 (en) * 2009-05-13 2014-05-06 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
WO2011151704A2 (en) * 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
US9745941B2 (en) * 2014-04-29 2017-08-29 Ford Global Technologies, Llc Tunable starter resistor
US10300026B2 (en) * 2015-08-24 2019-05-28 Shanxi Yabao Health Products Co., Ltd. Use of dihydroxyacetone in preparation of anti-cancer medicaments
CN111110676A (zh) * 2020-03-07 2020-05-08 天津医科大学总医院 阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
ATE278421T1 (de) 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
PL362740A1 (en) 2004-11-02
US20030153593A1 (en) 2003-08-14
CN102058588A (zh) 2011-05-18
AU2007201324A1 (en) 2007-04-19
WO2002040000A3 (en) 2002-09-06
ATE393629T1 (de) 2008-05-15
JP2004517065A (ja) 2004-06-10
SI1335725T1 (sl) 2008-08-31
JP2014088430A (ja) 2014-05-15
PL207061B1 (pl) 2010-10-29
US20070142425A1 (en) 2007-06-21
ZA200304603B (en) 2004-09-13
EP1335725B1 (en) 2008-04-30
AR031341A1 (es) 2003-09-17
CY1108109T1 (el) 2014-02-12
US7781446B2 (en) 2010-08-24
US7189735B2 (en) 2007-03-13
DK1335725T3 (da) 2008-06-30
AU2007201324B2 (en) 2010-11-18
MXPA03004192A (es) 2003-09-22
BR0115323A (pt) 2004-02-17
CA2429020C (en) 2009-05-26
IL155871A0 (en) 2003-12-23
KR20040029309A (ko) 2004-04-06
CN1678312A (zh) 2005-10-05
DE60133831D1 (de) 2008-06-12
IL155871A (en) 2012-03-29
SG148031A1 (en) 2008-12-31
ES2305134T3 (es) 2008-11-01
KR100827942B1 (ko) 2008-05-13
JP2010018620A (ja) 2010-01-28
JP4472251B2 (ja) 2010-06-02
US20020091137A1 (en) 2002-07-11
EA200300566A1 (ru) 2003-10-30
NO20032181D0 (no) 2003-05-14
JP2016094444A (ja) 2016-05-26
WO2002040000A2 (en) 2002-05-23
PT1335725E (pt) 2008-06-19
EP1335725A2 (en) 2003-08-20
DE60133831T2 (de) 2009-05-20
NZ539668A (en) 2007-06-29
CA2429020A1 (en) 2002-05-23
HUP0400521A3 (en) 2007-05-29
TWI286074B (en) 2007-09-01
HK1058008A1 (en) 2004-04-30
EA007096B1 (ru) 2006-06-30
HUP0400521A2 (hu) 2004-06-28
AU2731302A (en) 2002-05-27

Similar Documents

Publication Publication Date Title
NO20032181D0 (no) Anvendelse av CCI-779 som et antineoplastisk middel
EA200501251A1 (ru) Антинеопластические комбинации
DE69925133D1 (de) Pyrrolobenzodiazepine
NO20031672D0 (no) Aza- og polyaza-naftalenylkarboksamider for anvendelse som HIV-integraseinhibitorer
ATE302775T1 (de) Carbolinderivate
MXPA02012076A (es) Compuestos quimicos.
AU2001266575A1 (en) Chemical compounds
MXPA03002911A (es) Compuestos quimicos.
ATE346067T1 (de) Carbolinderivate
IL155590A0 (en) Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
NO20031648D0 (no) Farmasöytiske lösninger av modafinilforbindelser
BR0210101A (pt) Combinações antineoplásticas
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
AR034071A1 (es) Combinaciones antineoplasicas
AR033012A1 (es) Combinaciones antineoplasicas
DE60112960D1 (de) Kondensierte pyridoindolderivate
BR0209883A (pt) Uso de inibidores da proteasoma para o tratamento de distúrbios do olho seco
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
ATE259813T1 (de) Triazolopyrimidinderivate
NO20031414L (no) Ny oksabispidinforbindelse som er nyttig i behandlingen av hjertearrytmier
DE60127131D1 (de) Tricyclische imidazopyridine
DE60122559D1 (de) Indolderivate als pde5-inhibitoren
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
ES2185605T3 (es) 2,3-dihidro-1h-5,9-dioxaciclohepta (f) inden-7-onas 1,2-sustituidas y benzo (b) (1,4)dioxepin-3 onas 7-sustituidas.
NO20022253L (no) Middel til behandling av hepatitt C

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application